Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kymera Therapeutics (KYMR) Shares Outstanding (Weighted Average) (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed Shares Outstanding (Weighted Average) for 7 consecutive years, with $84.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Shares Outstanding (Weighted Average) rose 12.59% to $84.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $84.5 million, a 12.59% increase, with the full-year FY2025 number at $84.5 million, up 12.59% from a year prior.
  • Shares Outstanding (Weighted Average) was $84.5 million for Q4 2025 at Kymera Therapeutics, up from $82.7 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $84.5 million in Q4 2025 to a low of $44.6 million in Q1 2021.
  • A 5-year average of $62.7 million and a median of $58.3 million in 2023 define the central range for Shares Outstanding (Weighted Average).
  • Peak YoY movement for Shares Outstanding (Weighted Average): soared 2186.59% in 2021, then rose 6.93% in 2023.
  • Kymera Therapeutics' Shares Outstanding (Weighted Average) stood at $48.0 million in 2021, then grew by 12.39% to $53.9 million in 2022, then increased by 8.22% to $58.4 million in 2023, then increased by 28.58% to $75.0 million in 2024, then rose by 12.59% to $84.5 million in 2025.
  • Per Business Quant, the three most recent readings for KYMR's Shares Outstanding (Weighted Average) are $84.5 million (Q4 2025), $82.7 million (Q3 2025), and $80.3 million (Q2 2025).